Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arikace in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Infection
NCT01315691Phase 3Withdrawn
- Sponsor
- Insmed Incorporated
- Modality
- Small Molecules, Lipid-based Nanoparticles
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) and Pseudomonas aeruginosa infection comparing Arikace with Placebo (2 arms). Primary endpoint: Time to first protocol defined pulmonary exacerbation at 84 days. Status: withdrawn.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT01315691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01315691.